• $3.5M
    Market Cap
  • N/A
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTestâ„¢ Revenue and Expanding Commercial Opportunity

20/20 BioLabs announced a rescheduled investor webinar for September 2, 2026 at 2:00 p.m. ET to discuss Q2 2026 results featuring record OneTestâ„¢ revenue of $0.7 million (47.1% YoY increase), gross margin expansion to 41.7%, and commercial expansion across multiple channels including firefighter cancer screening programs.

08/28/2026, 6:26 PM • GlobeNewswire

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

20/20 BioLabs (Nasdaq: AIDX) announced the launch of a recurring monthly investor webinar series starting July 1, 2026, held on the first Wednesday of each month at 12:00 p.m. ET. The initiative aims to increase transparency, strengthen shareholder communication, and provide direct access to management regarding the company's AI-powered blood tests for early cancer detection and chronic disease prevention.

06/22/2026, 4:45 PM • GlobeNewswire

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

20/20 BioLabs (Nasdaq: AIDX) reported FY 2025 revenue of $2.0 million, up 17% year-over-year, with gross profit increasing 68% and gross margin expanding 900 basis points to 29.6%. The company achieved a 33% improvement in net loss to $3.7 million and reduced operating expenses by 35%. Recent highlights include a $5.0 million funding round, Nasdaq listing, $520,000 in Maryland state funding for firefighter cancer screenings, and launch of OneTest for Longevity. Management expects 2026 to be a breakout year driven by strong demand across firefighting, veterans, and occupational health markets.

03/31/2026, 4:57 PM • GlobeNewswire

Peers

No data found

No data found

Statistics

More
Day Range
$0.27
$0.28
$0.27
1-Year Range
$0.26
$23.85
$0.27
Latest Close$0.27
Change
+$0.005 (+1.92%)
Volume18,999
Market Cap$3.5M
Shares Outstanding12.8M
P/E (TTM)-0.51
Diluted EPS (TTM)-$0.53
Enterprise Value-$747,740.00

Information as of 10/21/2026

Company Profile

20/20 BIOLABS INC
https://2020biolabs.com
$3.5M
Market Cap
-$4.9M
Net Income
Sector: Healthcare
Industry: Medical Devices
15810 Gaither Road, Gaithersburg, MD, United States, 20877
240 453 6339

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Key Executives

  • Jonathan Cohen
  • Jiming Zhou
  • Michael S. Lebowitz
  • Marc Gordon
  • David Lees

Current Ownership Distribution

  • Other11.3M (88.61%)
  • Institutions841,045 (6.59%)
  • Insiders602,936 (4.72%)
  • Mutual Funds10,638 (0.08%)